Related references
Note: Only part of the references are listed.Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
Katja Hatz et al.
ACTA OPHTHALMOLOGICA (2017)
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire et al.
OPHTHALMOLOGY (2016)
Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
Karina Berg et al.
OPHTHALMOLOGY (2015)
Recent developments in the treatment of age-related macular degeneration
Frank G. Holz et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION
Nicholas Toalster et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact
Gary Shienbaum et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab
Paul Mitchell
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration
Hassiba Oubraham et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact
Omesh P. Gupta et al.
OPHTHALMOLOGY (2010)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting
Suman Pilu et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Tolerability and efficacy of multiple escalating doses of ranibizumab (lucentis) for neovascular age-related macular degeneration
PJ Rosenfeld et al.
OPHTHALMOLOGY (2006)
Share Paper
